Toby Maher

1 month ago | ajmc.com | Pearl Steinzor |Toby Maher

Nerdandomilast has the potential to become a critical new treatment option for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), offering hope where previous clinical trials have failed, says Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC. This transcript was lightly edited; captions were auto-generated. TranscriptBoth FIBRONEER trials met their primary end point of reduced forced vital capacity (FVC) decline.

Nov 8, 2024 | ajmc.com | Toby Maher

OpinionVideoNovember 8, 2024Author(s): Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment efficacy, and increased morbidity. Contributing factors to treatment delays include healthcare system inefficiencies, patient-related barriers, and logistical challenges.

Oct 31, 2024 | ajmc.com | Toby Maher

OpinionVideoOctober 31, 2024Author(s): Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation. Comprehensive evaluation is crucial to tailor treatment plans addressing both IPF and comorbidities effectively. Comorbidities may limit therapeutic options, necessitate medication adjustments, or require additional interventions.

Oct 24, 2024 | ajmc.com | Toby Maher

OpinionVideoOctober 24, 2024Author(s): IPF diagnosis relies on clinical evaluation, HRCT, and occasionally lung biopsy to identify usual interstitial pneumonia patterns. The average time to IPF diagnosis can be delayed up to two years due to symptom overlap with other conditions. Early diagnosis is crucial for influencing disease progression and treatment efficacy, enabling timely intervention with antifibrotic therapies.

Oct 17, 2024 | ajmc.com | Toby Maher

OpinionVideoOctober 17, 2024Author(s):Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial lung disease characterized by progressive lung scarring, which leads to significant respiratory impairment and distinct clinical challenges compared with other interstitial lung diseases. Video content above is prompted by the following:What is IPF, and how does IPF compare with interstitial lung disease?